Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions
NCT05742347 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47
Last updated 2025-05-21
Summary
This study will evaluate the efficacy of the DriGo skin protectant textile (SPT) to manage erythema, maceration, denudation, satellite lesions, pain, itching, burning, moisture, and odor associated with skin folds (henceforth together referred to as "skin fold conditions"). Participants will be patients with skin fold conditions, which will be treated with the SPT. Healthcare providers will apply the SPT to the participants' target areas. A given participant can have up to two target areas enrolled in the study. An independent licensed clinician with experience in identifying and treating skin fold conditions, will use photographs of the skin folds and other skin-on-skin contact areas (henceforth referred to as "target area\[s\]") to assess the status of erythema, maceration, denudation, and satellite lesions in the target areas when the SPT is first applied (Day 0), and on Days 1, 3, and 5, during SPT changes. The Principal Investigator (PI) or qualified designee will take photographs of the target areas and assess moisture and odor in these areas. Participants will provide their impressions of pain, itching and burning in the target area(s) on the same days as the skin fold condition photography. In addition, the study will include feedback from the Health Care Providers (HCPs) about the SPT and overall experience of the participants with the SPT.
Conditions
- Erythema
- Maceration
- Lesion Skin
- Skin Folds
Interventions
- DEVICE
-
DriGo Skin Protectant Textile
All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
Sponsors & Collaborators
-
Medline Industries
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-07-01
- Primary Completion
- 2024-08-12
- Completion
- 2024-09-26
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
NCT05979831 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers
NCT00001164 ·Status: COMPLETED
-
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
NCT01538862 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
NCT02670330 ·Status: TERMINATED ·Phase: PHASE3
-
Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)
NCT01078987 ·Status: TERMINATED ·Phase: PHASE4
-
Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels
NCT01014754 ·Status: COMPLETED
-
Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB
NCT02004600 ·Status: WITHDRAWN ·Phase: NA
-
Gene First Approach to Connective Tissue Disease
NCT04664478 ·Status: COMPLETED
-
Study of Scaling Disorders and Other Inherited Skin Diseases
NCT00001292 ·Status: COMPLETED
-
Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)
NCT05143190 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
NCT02975271 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
NCT02037347 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
NCT02152007 ·Status: COMPLETED ·Phase: PHASE1
-
Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine
NCT02465476 ·Status: COMPLETED ·Phase: NA
-
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
NCT03585946 ·Status: WITHDRAWN
-
Evaluate the Evolution of Body and Scalp Skin Discomfort in Patients With Hereditary Ichthyosis After Wraps (EnvelopIchtyose)
NCT05979506 ·Status: RECRUITING ·Phase: NA
-
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
NCT02426229 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
NCT03740724 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)
NCT02887495 ·Status: COMPLETED
-
Optical Frequency Domain Imaging (OFDI) in Dermatology
NCT01438047 ·Status: WITHDRAWN
-
Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI
NCT01124513 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis
NCT00574613 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NCT03752905 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
NCT07090226 ·Status: RECRUITING ·Phase: NA
-
Addressing Inequity in Dermatology
NCT06056648 ·Status: RECRUITING